Tubulin tyrosine ligase (TTL) is a cytosolic enzyme that catalyzes the post-translational addition of tyrosine to the C-terminal end of detyrosinated alpha-tubulin 1, completing a cycle of detyrosination and tyrosination that regulates microtubule stability and dynamics 1. TTL functions as a key regulator of the microtubule cytoskeleton, positively regulating mitotic cell cycle progression and metaphase plate congression 2. Recent studies demonstrate significant clinical relevance: chr2 TTL activation improves cardiac contractility, diastolic function, and stroke volume in hypertrophic cardiomyopathy models by reducing microtubule detyrosination 2. In cardiac conduction, TTL-mediated tubulin tyrosination is essential for maintaining proper adherens junction organization and ventricular conduction velocity; TTL knockdown rescues functional deficits in Brugada syndrome models by restoring the detyrosinated tubulin fraction critical for microtubule stability 3. In cancer biology, TTL is upregulated in hepatocellular carcinoma as part of the chromosome 2 gene set, with high expression associated with poor overall survival 4. The gene localizes to human chromosome 2 and mouse chromosome 2 1. These findings establish TTL as a potential therapeutic target for cardiac diseases and suggest its involvement in cancer pathophysiology through microtubule-dependent processes.